Åbo Akademi University is a Swedish-language multidisciplinary university located in Turku, Finland. It was founded in 1918 and is the only exclusively Swedish-language multi-faculty university in Finland. The university is recognized for its research output in various biological subfields, including cell biology, genetics, and nanotechnology.
Åbo Akademi University is the NAP4DIVE coordinator. They are involved in several of the project’s technical developments, such as the production of synthetic nanoparticles, characterisation of nanoparticle-cell interaction, the NP design library, as well as development, training and validation of the digital NP design simulator
Finnadvance produces organs-on-chip for preclinical drug testing and personalized medicine. We de-risk drug development by providing relevant in vitro models through the use of our high throughput organ-on-chip technology, named AKITA.
Finnadvance will be responsible of the development and fabrication of the blood-brain barrier-on-chip platform. It includes the AKITA microfluidic plates, multiple cell types from the blood-brain barrier and Trans-Epithelial/Endothelial Electrical Resistance (TEER) measurements.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom.
They are involved in several of the project’s validation activities, such as the testing of synthetic nanoparticles in microphysiological systems and in transgenic mouse models
The University of Gothenburg is one of Sweden’s largest universities with a wide range of education and research. The university was founded in 1891 and today has more than 58,000 students and 6,800 employees. The university is internationally recognized for its research profile across several disciplines, including neuroscience, molecular biology, immunology, and nanomedicine.
The University of Gothenburg will contribute to the development of biologically derived nanoparticles (Bio-NPs) from various cell types, including central nervous system (CNS) cells. The team will focus on the incorporation of RNA-based drugs (such as mRNA) into these Bio-NPs, and on the isolation and characterization of specific Bio-NP subpopulations capable of efficiently crossing the blood-brain barrier (BBB).
Chalmers University of Technology is a private research university located in Gothenburg, Sweden and funded in 1829 following a donation by William Chalmers, a director of the Swedish East India Company. Chalmers focuses on engineering and science. The university has approximately 3100 employees and 10,000 students. Chalmers coordinates the development of a Swedish quantum computer and the Graphene Flagship, a European Union research initiative to develop commercial technologies with graphene.
Chalmers is involved and responsible for the Characterisation of the Nanoparticle-cell interaction
The Microfluidics Innovation Center (MIC) is an innovative company (SME) based in Paris, France. With expertise in flow control instruments and microfluidics, the main mission of the company is to provide state-of-the-art instruments to scientists to help them achieve major advances in their research field, by facilitating the access of non-specialists (chemists, biologists) to microfluidics. For this, the MIC collaborates closely with academic and industrial partners to develop easy-to-use and robust automated microfluidic systems.
The MIC will develop a fluidic system to supplement the cells in the Blood-Brain-Barrier (BBB) with growth media and to inject the nanoparticle formulations to be tested. For this task, the MIC will collaborate closely with Finnadvance to develop the BBB in vitro model, and with the whole consortium to determine the best culture and testing conditions.
Delft University of Technology is the oldest and largest technical university in the Netherlands, located in Delft. Renowned for its high-quality research and education in engineering and technology, TU Delft has a strong international reputation in fields such as computer science, artificial intelligence, and biomedical engineering. The university is recognised for its interdisciplinary approach and close collaboration with industry and academic partners.
Delft University of Technology (TUDelft) is the Work Package leader for WP3 and WP4. TUDelft is responsible for developing the computational model that predicts the efficacy of drug carriers in crossing the blood-brain barrier. In addition, the team is applying explainable artificial intelligence (XAI) techniques to uncover the factors driving the superior performance of specific nanoparticle designs, enhancing the accuracy, transparency, and reliability of predictive modelling within the project.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi. Nam eget dui. Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet
adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc,
Betthera s.r.o. is a Czech consulting company specializing in health economics, regulatory affairs, and social impact assessments. Their mission is to deliver high-quality services that aid clients in developing, implementing, and marketing medical technologies sustainably and ethically. Betthera evaluates the economic efficiency and effectiveness of investments in healthcare and emerging technologies, providing valuations in contexts such as economic, social, demographic, and quality of life aspects. They also conduct gap analyses of clients’ regulatory strategies, designing necessary steps for successful medical device conformity assessments.
In the NAP4DIVE project, Betthera s.r.o. is responsible for conducting a comprehensive Health Technology Assessment (HTA) to determine the feasibility and usability of the assessed alternatives. This assessment will analyze the expected outcomes and impacts, providing evidence for public or private investors.
AMIRES S.R.O. is a consulting company for research, development and innovation projects. Their main strength is the creation of new international sustainable partnerships within innovation focused value chains. Their developed projects remain the main enablers for our industrial clients and their growth and provide the important opportunities for R&D community.
AMIRES will support the coordinator, AAU, in Project Management and Coordination and will lead Dissemination and communication activities.
Eindhoven University of Technology, founded in 1956, is a technical university in the Netherlands, located in the Brainport Region. The university is recognized for its research in many science and engineering fields, and is also home to a thriving Philosophy and Ethics group carrying out applied ethics and philosophy of science research.
Eindhoven University of Technology provides ethics and trustworthiness deliverables across several work packages in the project. They examine scenarios and decisions emerging from NAP4DIVE technologies to create ethics guidelines and increase ethical and societal impact, influencing key stakeholders to adopt non-animal models for fundamental medical research.